-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Eyenovia today announced that its proprietary pilocarpine formula MicroLine has reached the primary endpoint in the Phase 3 clinical trial VISION-1 for the treatment of presbyopia patients, significantly improving the near vision of adult patients with presbyopia.
Presbyopia is an age-related progressive hardening of the lens of the eye, making it difficult for the transparent lens of the eye to change shape.
The VISION-1 study evaluated the safety and effectiveness of Eyenovia's 1% and 2% pilocarpine formulations MicroLine compared with placebo.
VISION-1 reached its primary endpoint.
At the same time, MicroLine was well tolerated, with all adverse events being mild and no serious adverse events.
Note: The original text has been deleted
Reference materials:
[1] Eyenovia Announces Positive Topline Results from VISION-1 Phase 3 Clinical Study of MicroLine for the Treatment of Presbyopia.